Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
FLT3/AXL Inhibitor (A... 2020.06.22  
 회사연혁

Oscotec Inc. History


2020

  1. Mar. Dr. Yoon Taeyoung inaugurated as Separate CEO

2019

  1. Oct. Initiation of SYK inhibitor’s Phase 2 clinical trial for ITP drug candidate

2018

  1. Nov. L/O of EGFR-Targeted Anti-Cancer Drug (Yuhan to Janssen Biotech.)
  2. Oct. Drug candidate for Rheumatoid Arthritis selected as KDDF sponsored Project (Phase 2 clinical trial)

2017

  1. Dec. Commencement of Phase 1 clinical trial of FLT3-Targeted drug candidate for AML
  2. Jul. Completion of SYK inhibitor's FDA Phase 1 clinical trial for Rheumatoid Arthritis in US

2016

  1. Oct. Approval for Phase 1 clinical trial of FLT3-Targeted drug candidate for AML
  2. Oct. IND and CTA of FLT3, AML drug
  3. Apr. GENOSCO separated into R&D company (Moved to Head quarter in Boston)
  4. Jan. Selected for Korea Drug Development Fund (KDDF) project Development of SYK inhibitor for Rheumatoid Arthritis (Phase 1 clinical trial)

2015

  1. Dec. Complete in Pre-clinical study for AML drug
  2. Sep. IND and CTA of SYK, inhibitor Rheumatoid Arthritis
  3. Jul. Licensing Out EGFR, non-small-cell-lung-cancer drug candidate

2014

  1. Jun. Selected for Ministry of Health & Welfare’s R&D project Development of FLT3 inhibitor for the treatment of acute myeloid leukemia
  2. May Selected for Korea Drug Development Fund (KDDF) project Development of SYK inhibitor for rheumatoid Arthritis

2013

  1. Oct. Ministry of Science, ICT and future planning-Development of Novel Drug for Parkinson’s disease

2012

  1. May AML drug pre-clinical test

2011

  1. Aug. R&D Center moved into Korea Bio Park and expanded to become Oscotec Central R&D Center
  2. Mar. Licensing out BT-301, periodontal drug candidate, to Yuhan Pharmaceutical
More View
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.